Myelosuppression In Extensive Stage Small Cell Lung Cancer Therapeutics
1. Cosela patent expiration
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell l...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10189849 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(5 years from now) | |
| US9957276 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(5 years from now) | |
| US12168666 | PHARMACOSMOS | Morphic forms of trilaciclib and methods of manufacture thereof |
Nov, 2040
(14 years from now) | |
| US8598197 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(5 years from now) | |
| US8598186 | PHARMACOSMOS | CDK inhibitors |
Dec, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10085992 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(8 years from now) | |
| US9487530 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(8 years from now) | |
| US11529352 | PHARMACOSMOS | Preservation of immune response during chemotherapy regimens |
Jul, 2039
(13 years from now) | |
| US11717523 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(8 years from now) | |
| US10966984 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(8 years from now) | |
| US10927120 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(5 years from now) | |
| US11040042 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Oct, 2031
(5 years from now) | |
| US10189850 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Dosage: POWDER
More Information on Dosage
COSELA family patents
